We have amassed a world-class autophagy drug discovery team that is working and learning together. By leveraging our deep understanding of autophagy and dynamics, we established the PHLYT™ platform to expand targeted degradation in ways previously unimagined.

In-house validation has identified definitive autophagy targets that can be drugged with chemistry to form the foundation of PHLYT™. Degradation 2.0 is modular because this autophagy-targeting chemistry can be used to develop specific degraders for rare and common diseases.

PHLYT™ Platform

Heterobifunctional chemistry has been developed to facilitate the recruitment of autophagy regulators to disease targets leading to autophagosome biogenesis around the target. We have demonstrated that this approach has the capacity to degrade several disease targets in a robust way.

Key components of PHLYT™

  • Autophagy knowledge

    Our team has the leading autophagy industry experts, world-class R&D capabilities, and a broad network of academic pioneers working on autophagy and proteostasis.

  • Target identification

    Our deep expertise in autophagy, disease processes, and chemical biology has enabled the discovery of autophagy proteins that can degrade multiple disease targets.

  • Ligand discovery

    Our autophagy small-molecule ligand-discovery engine enables the development of PHLYT™ degraders. We own the ligands to make Degradation 2.0 a reality.

  • Disease targets

    Knowing where and how to deploy the PHLYT™ technology is critical for successful therapeutic development. We understand the molecular features of disease targets that place them in the sweet-spot for PHLYT™-mediated degradation.






Casma wholly owned pipeline

Casma's PHLYT™ technology can degrade many disease targets that go beyond the capacity of the ubiquitin-proteasome system. We are advancing a discovery pipeline of degraders that will eliminate several drivers of disease. Some of these programs will be developed on our own and others through partnership.

Program Exploratory Discovery Preclinical
Oncology Program 1
Oncology Program 2
Inflammation Program 1


Get in touch

For general questions, media inquiries, or to learn more about collaborations and partnerships, click below.

Get in touch

About us

Breaking new ground in autophagy drug discovery.

Meet our team

The science: autophagy

Learn what autophagy is, how it works, and why it matters.

Explore the science